Skip to main content
SpringerLink
Log in

Comparative Evaluations of tPA vs SK with Particular Reference to the GUSTO-I Trial

  • Chapter
Fibrinolytics and Antifibrinolytics

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 146))

  • 164 Accesses

Abstract

The benefits of intravenous (i.v.) thrombolytic therapy in acute myocardial infarction (AMI) are now well established. This chapter will briefly review the evidence demonstrating therapeutic benefit of thrombolytic therapy and the focus on the recent major comparative randomized clinical trials of tissue-type plasminogen activator (tPA) vs streptokinase (SK) and, in particular, the Global Utilization of SK and tPA for Occluded Coronary Arteries (GUSTO-I) randomized trial of strategies employing tissue plasminogen activator or SK or both.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anderson RD, Ohman EM, Holmes DR, Jr, Col I, Stebbins AL, Bates ER, Stomel RJ, Granger CB, Topol EJ, Califf RM, for the GUSTO-1 investigators (1997) Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 30:708–715

    Article  PubMed  CAS  Google Scholar 

  • Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M (1992) Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 20:513–519

    Article  PubMed  CAS  Google Scholar 

  • Aylward PE, Wilcox RG, Horgan JH, White HD, Granger CB, Califf RM, Topol EJ, for the GUSTO-I Investigators (1996) Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. Ann Intern Med 125:891–900

    PubMed  CAS  Google Scholar 

  • Barbagelata NA, Granger CB, Oqueli E, Suárez LD, Borruel M, Topol EJ, Califf RM (1997) TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. Am Heart J 133:273–282

    Article  PubMed  CAS  Google Scholar 

  • Berger PB, Holmes DR, Jr, Stebbins AL, Bates ER, Califf RM, Topol EJ, for the GUSTO-1 investigators (1997) Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. Circulation 96:122–127

    Article  PubMed  CAS  Google Scholar 

  • Bleich SD, Nichols TC, Schumacher RR, Cook DH, Tate DA, Teichman SL (1990) Effect of heparin on coronary arterial patency after thrombolysis with tissue

    Google Scholar 

  • Bruce CJ, Christian TF, Schaer GL, Spaccavento LJ, Jolly MK, O’Connor MK, Gibbons RJ (1999) Determinants of infarct size after thrombolytic treatment in acute myocardial infarction. Am J Cardiol 83:1600–1605

    Article  PubMed  CAS  Google Scholar 

  • Califf RM, Stump D, Topol EJ, Mark DB (1999) Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. Am Heart J 137 [Suppl S]:S90–S93

    Article  PubMed  CAS  Google Scholar 

  • Califf RM, Topol EJ, Stack RS, Ellis SG, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Anderson JL, Harrelson-Woodlief L, Wall TC, Phillips III HR, Abbottsmith CW, Candela RJ, Flanagan WH, Sasahara AA, Mantell SJ, Lee KL, for the TAMI Study Group (1991) Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction — phase 5 randomized trial. Circulation 83:1543–1556

    Article  PubMed  CAS  Google Scholar 

  • Califf RM, White HD, Van de Werf EV, Sadowski Z, Armstrong PW, Vahanian A, Simoons ML, Simes RJ, Lee KL, Topol EJ, for the GUSTO-I Investigators (1996) One-year results from the global utilization of streptokinase and TPA for occluded coronary arteries (GUSTO-I) trial. Circulation 94:1233–1238

    Article  PubMed  CAS  Google Scholar 

  • Califf RM, Woodlief LH, Harrell FE, Jr, Lee KL, White HD, Guerci A, Barbash GI, Simes RJ, Weaver WD, Simoons ML, Topol EJ, for the GUSTO-I Investigators (1997) Selection of thrombolytic therapy for individual patients: development of a clinical model. Am Heart J 133:630–639

    Article  PubMed  CAS  Google Scholar 

  • Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri ST, Davis V, Gibson CM, Poole WK, Braunwald E, for the TIMI 4 Investigators (1994) Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trial. J Am Coll Cardiol 24:1602–1610

    Article  PubMed  CAS  Google Scholar 

  • Carney RJ, Murphy GA, Brandt TR, Daley PJ, Pickering E, White HJ, McDonough TJ, Vermilya SK, Teichman SL, for the RAAMI Study Investigator (1992) Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. J Am Coll Cardiol 20:17–23

    Article  PubMed  CAS  Google Scholar 

  • Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E (1987) Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76:142–154

    Article  PubMed  CAS  Google Scholar 

  • Dalen JE, Gore JM, Braunwald E, Borer J, Goldberg RJ, Passamani ER, Forman S, Knatterud G, and the TIMI Investigators (1988) Six-and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. Am J Cardiol 62:179–185

    Article  PubMed  CAS  Google Scholar 

  • de Bono DP, Simoons ML, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, Bescos LL, Mueller E, Pfisterer M, Van de Werf F, Zijlastra F, Verstraete M (1992) Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial (ECSG-6). Br Heart J 67:122–128

    Article  PubMed  Google Scholar 

  • Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343:311–322

    Google Scholar 

  • Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ, Califf RM, for the GUSTO Investigators (1995) Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-trial. Circulation 92:2811–2818

    Article  PubMed  CAS  Google Scholar 

  • Grines CL, DeMaria AN (1990) Optimal utilization of thrombolytic therapy for acute myocardial infarction: concepts and controversies. J Am Coll Cardiol 16:223–231

    Article  PubMed  CAS  Google Scholar 

  • Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI) (1990) GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 336:65–71

    Google Scholar 

  • Hasdai D, Califf RM, Thompson TD, Hochman JS, Ohman EM, Pfisterer M, Bates ER, Vahanian A, Armstrong PW, Criger DA, Topol EJ, Holmes DR Jr. (2000) Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 35:136–143

    Article  PubMed  CAS  Google Scholar 

  • Hasdai D, Holmes DR Jr, Califf RM, Thompson TD, Hochman JS, Pfisterer M, Topol EJ, for the GUSTO-I Investigators (1999) Cardiogenic shock complicating acute myocardial infarction: predictors of death. Am Heart J 138:21–31

    Article  PubMed  CAS  Google Scholar 

  • Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, Berger PB, Topol EJ, for the GUSTO-I Investigators (1995a) Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. J Am Coll Cardiol 26:668–674

    Article  PubMed  Google Scholar 

  • Holmes DR Jr, Califf RM, Topol EJ (1995b) Lessons we have learned from the GUSTO trial. J Am Coll Cardiol 25 [Suppl]:10S–17S

    Article  PubMed  Google Scholar 

  • Holmes DR Jr, Califf RM, Van de Werf F, Berger PB, Bates ER, Simoons MLW, White HD, Thompson TD, Topol EJ, for the GUSTO-I Investigators (1997) Difference in countries’ use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet 349:75–78

    Article  PubMed  Google Scholar 

  • Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators (1990) A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 323:1433–1437

    Article  PubMed  CAS  Google Scholar 

  • Hsia J, Kleiman N, Aguirre F, Chaitman BR, Roberts R, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators (1992) Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. J Am Coll Cardiol 20:31–35

    Article  PubMed  CAS  Google Scholar 

  • ISIS-3 (Third International Study of Infarct Survival) Collaborative Group (1992) ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 339:753–770

    Article  Google Scholar 

  • Kingston IB, Castro MJM, Anderson S (1995) In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid β-peptide analogues. Nat Med 1:138–142

    Article  PubMed  CAS  Google Scholar 

  • Klarich KW, Christian TF, Higano ST, Gibbons RJ (1999) Variability of myocardium at risk for acute myocardial infarction. Am J Cardiol 83:1191–1195

    Article  PubMed  CAS  Google Scholar 

  • Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, Holmes DR, Bates E, Pfisterer M, Vahanian A, Topol EJ, for the GUSTO Investigators (1994) Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. Circulation 90:2658–2665

    Article  PubMed  CAS  Google Scholar 

  • Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM, for the GUSTO-I Investigators (1995) Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41021 patients. Circulation 91:1659–1668

    Article  PubMed  CAS  Google Scholar 

  • Lincoff AM, Topol EJ (1993) Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?. Circulation 88:1361–1374

    Article  PubMed  CAS  Google Scholar 

  • Magnani B, for the PAIMS Investigators (1989) Plasminogen Activator Italian Multicenter Study (PAIMS): Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 13:19–26

    Article  PubMed  CAS  Google Scholar 

  • Mahaffey KW, Granger CB, Sloan MA, Thompson TD, Gore JM, Weaver WD, White HD, Simoons ML, Barbash GI, Topol EJ, Califf RM, for the GUSTO-I Investigators (1998) Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. Circulation 97:757–764

    Article  PubMed  CAS  Google Scholar 

  • Mahaffey KW, Granger CB, Toth CA, White HD, Stebbins AL, Barbash GI, Vahanian A, Topol EJ, Califf RM, for the GUSTO-1 investigators (1997) Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. J Am Coll Cardiol 30:1606–1610

    Article  PubMed  CAS  Google Scholar 

  • Mak K-H, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ, for the GUSTO-1 investigators (1997) Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 30:171–179

    Article  PubMed  CAS  Google Scholar 

  • Mak K-H, Topol EJ (2000) Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. J Am Coll Cardiol 35:563–568

    Article  PubMed  CAS  Google Scholar 

  • Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight JD, Harrell FE Jr, Simes J, Topol EJ (1995) Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 332:1418–1424

    Article  PubMed  CAS  Google Scholar 

  • Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U (1989) Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 14:1566–1569

    Article  PubMed  CAS  Google Scholar 

  • Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W, Limbourg P, Merx W, Haerten K (1992) Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 19:885–891

    Article  PubMed  CAS  Google Scholar 

  • Reiner JS, Lundergan CF, Fung A, Coyne K, Cho S, Israel N, Kazmierski J, Pilcher G, Smith J, Rohrbeck S, Thompson M, Van de Werf F, Ross AM, for the GUSTO-1 Angiographic Investigators (1996) Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. Circulation 94:2441–2446

    Article  PubMed  CAS  Google Scholar 

  • Rentrop P, Blanke H, Karsch KR, Kaiser H, Köstering H, Leitz K (1981) Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 63:307–317

    Article  PubMed  CAS  Google Scholar 

  • Ross AM, Coyne KS, Moreyra E, Reiner JS, Greenhouse SW, Walker PL, Simoons ML, Draoui YC, Califf RM, Topol EJ, Van de Werf F, Lundergan CF, for the GUSTO-I Angiographic Investigators (1998) Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Circulation 97:1549–1556

    Article  PubMed  CAS  Google Scholar 

  • Simes RJ, Topol EJ, Holmes DR, Jr., White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, Ross AM, for the GUSTO-I Investigators (1995) Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 91:1923–1928

    Article  PubMed  CAS  Google Scholar 

  • Tardiff BE, Califf RM, Morris D, Bates E, Woodlief LH, Lee KL, Green C, Rutsch W, Betriu A, Aylward PE, Topol EJ, for the GUSTO Investigators (1997) Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. J Am Coll Cardiol 29:240–249

    Article  PubMed  CAS  Google Scholar 

  • The GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615–1622

    Article  Google Scholar 

  • The GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682

    Article  Google Scholar 

  • The International Study Group (1990) In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 336:71–75

    Article  Google Scholar 

  • The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349–360

    Google Scholar 

  • The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587

    Article  Google Scholar 

  • The TIMI Study Group (1985) The thrombolysis in myocardial infarction (TIMI) trial: phase 1 findings. N Engl J Med 312:932–936

    Google Scholar 

  • Topol EJ, Armstrong P, Van de Werf F, Kleiman N, Lee K, Morris D, Simoons M, Barbash G, White H, Califf RM, on behalf of the GUSTO Steering Committee (1992) Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. J Am Coll Cardiol 19:1123–1128

    Article  PubMed  CAS  Google Scholar 

  • Topol EJ, Califf RM, Lee KL (1994) More on the GUSTO trial. N Engl J Med 331:277–278

    Article  PubMed  CAS  Google Scholar 

  • Topol EJ, George BS, Kereiakes DJ, Candela RJ, Abbottsmith CW, Stump DC, Boswick JM, Stack RS, Califf RM, and the TAMI Study Group (1988) Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction. Am J Cardiol 61:723–728

    Article  PubMed  CAS  Google Scholar 

  • Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM, and the TAMI Study Group (1989) A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction (TAMI-3). Circulation 79:281–286

    Article  PubMed  CAS  Google Scholar 

  • Tracy RP, Rubin DZ, Mann KG, Bovill EG, Rand M, Geffken D, Tracy PB (1997) Thrombolytic therapy and proteolysis of factor V. J Am Coll Cardiol 30:716–724

    Article  PubMed  CAS  Google Scholar 

  • Van de Werf F, Topol EJ, Lee KL, Woodlief LH, Granger CB, Armstrong PW, Barbash GI, Hampton JR, Guerci A, Simes RJ, Ross AM, Califf RM, for the GUSTO Investigators (1995) Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries: results from the GUSTO trial. JAMA 273:1586–1591

    Article  PubMed  Google Scholar 

  • Verstraete M, Bernard R, Bory M, Brower RW, Collen D, de Bono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Schartl M, Schmidt W, Uebis R, von Essen R (1985) Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1:842–847

    Article  PubMed  CAS  Google Scholar 

  • Wall TC, Califf RM, George BS, Ellis SG, Samaha JK, Kereiakes DJ, Worley SJ, Sigmon K, Topol EJ, for the TAMI-7 Study Group (1992) Accelerated plasminogen activator dose regimens for coronary thrombolysis: the TAMI-7 Study Group. J Am Coll Cardiol 19:482–489

    Article  PubMed  CAS  Google Scholar 

  • White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, Sharpe DN, Whitlock RML, Norris RM (1989) Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med 320:817–821

    Article  PubMed  CAS  Google Scholar 

  • Wnendt S, Wetzels I, Günzler WA (1997) Amyloid-β peptides stimulate tissue-type plasminogen activator but not recombinant prourokinase. Thromb Res 85:217–224

    Article  PubMed  CAS  Google Scholar 

  • Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topol EJ, Ross AM, for the GUSTO-I Angiographic Investigators (1996) Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 28:1661–1669

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. C. Chiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. J. Topol
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. FRAT — Hôpital Nestlé 2077, CHUV, CH-1011, Lausanne, Switzerland

    F. Bachmann

  2. Chemin Praz Mandry 20, CH-1052, Le Mont, Switzerland

    F. Bachmann

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Chiu, A.C., Topol, E.J. (2001). Comparative Evaluations of tPA vs SK with Particular Reference to the GUSTO-I Trial. In: Bachmann, F. (eds) Fibrinolytics and Antifibrinolytics. Handbook of Experimental Pharmacology, vol 146. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56637-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56637-0_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63029-3

  • Online ISBN: 978-3-642-56637-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation